GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Total Payout Ratio

Aadi Bioscience (FRA:3350) Total Payout Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Aadi Bioscience's current Total Payout Ratio is 0.00.


Aadi Bioscience Total Payout Ratio Historical Data

The historical data trend for Aadi Bioscience's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Total Payout Ratio Chart

Aadi Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
- 1.37 1.20 -

Aadi Bioscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aadi Bioscience's Total Payout Ratio

For the Biotechnology subindustry, Aadi Bioscience's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aadi Bioscience's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Total Payout Ratio falls into.



Aadi Bioscience Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Aadi Bioscience's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -60.307
=0.00

Aadi Bioscience's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -16.826
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aadi Bioscience Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aadi Bioscience (FRA:3350) Business Description

Traded in Other Exchanges
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines